9:25 am Chair’s Opening Remarks
Delving into Claudin Biology & Translational Success in Claudin-Targeted Therapies
9:30 am Panel Discussion: Insights into Claudin Biology & its Impact On Cancer Progression
Synopsis
- Understanding the dynamic expression patterns of Claudin 18.2, 6, and 9 in different cancer stages and the implications for therapeutic targeting
- Outlining the role of claudin proteins in tumor microenvironment interactions and how these interactions influence cancer progression and metastasis
- Identifying how understanding claudin biology can inform clinical strategies and improve therapeutic outcomes, including the development of targeted delivery systems and combination therapies
10:00 am Translational Development: Bridging Preclinical Findings to Clinical Success in Claudin-Targeted Therapies
Synopsis
- Understanding the importance of developing companion diagnostics for Claudintargeted therapies, including the identification and validation of biomarkers to ensure patient selection
- Showcasing strategies to address challenges in translational development, such as achieving target specificity, managing toxicity profiles, and optimizing therapeutic windows
- Analyzing case studies highlighting the successful transition of Claudin-targeted therapies from preclinical stages to clinical trials, with a focus on lessons learned and best practices
10:30 am Showcasing Claudin18.2 T Cell Engager for GC & PDAC Malignancies
Synopsis
- Reviewing CLDN18.2 expression as a target for GC and PDAC tumours
- Strategies for increasing the therapeutic index of T cell engagers and application to CLDN18.2
- Preclinical data on AZD5863 – a clinical stage CLDN18.2 T cell engager
11:00 am Virtual Networking Session
Synopsis
Return to refreshed breakout groups to reconnect and break down your takeaways so far, alongside some discussion questions to tackle with your fellow attendees.
11:30 am Coffee Break
Assessing Innovative Therapeutic Approaches & Toxicity Management in Claudin-Targeted Therapies
12:00 pm Next-Generation Cell Therapies Targeting Claudin: Overcoming Challenges & Improving Outcomes
Synopsis
- Showcasing the latest advancements in next-generation cell therapies targeting claudin, emphasizing novel approaches beyond CAR-T
- Understanding improvements in toxicity profiles and the durability of therapeutic responses in solid tumors
- Highlighting early clinical data and preclinical insights to illustrate the effectiveness and potential of these innovative therapies
12:30 pm Potent next-gen ISAC targeting Claudin 18.2
Synopsis
Efficacy in low-antigen-density tumors
Demonstrated superiority to ADCs in preclinical studies
Immunologic memory with epitope spreading provides promise of durable responses and prevents recurrence MTD ≥ 12 mg/kg in NHPs with differentiated toxicology profile from cytotoxic ADCs
Preparing for first-in-human clinical trial
12:45 pm Translational Development: Bridging Preclinical Findings to Clinical Success in Claudin-Targeted Therapies
Synopsis
- Understanding the importance of developing companion diagnostics for Claudintargeted therapies, including the identification and validation of biomarkers to ensure patient selection
- Showcasing strategies to address challenges in translational development, such as achieving target specificity, managing toxicity profiles, and optimizing therapeutic windows
- Analyzing case studies highlighting the successful transition of Claudin-targeted therapies from preclinical stages to clinical trials, with a focus on lessons learned and best practices